The healthcare sector has been making headlines recently, with many calling for regulatory and systemic reforms

as insurance premiums are expected to rise by up to 70% next year. As a result, the Health Ministry has proposed that diagnosis-related group pricing system, (DRG) be implemented. Oong Chun Sung, Equity Research Analyst, RHB Investment Bank tells us if DRG will be a boom or bane for earnings and which listed companies stand to benefit.

Image Credits: Shutterstock.com